Loading
Life sciences · Journal article
Cancer Immunology Immunotherapy · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract High-dose vitamin C (HDVC) exhibits antitumor and immunomodulatory properties and may enhance the efficacy of immune checkpoint inhibitors (ICIs); however, its ability to reprogram the immunosuppressive tumor microenvironment (TME) in pancreatic cancer, particularly through modulating tumor-associated macrophage (TAM) polarization, remains unclear. In this study, the antitumor activity of HDVC was evaluated in a subcutaneous KPC mouse model, while in vitro models utilizing lipopolysaccharide (LPS) + IFN-γ-stimulated mouse and human macrophages were employed to investigate polarization. Mechanisms were probed by RNA sequencing, western blotting, flow cytometry, pharmacological inhibition, and siRNA-mediated JAK2 knockdown. Macrophage involvement was confirmed in vivo via clodronate liposome-mediated depletion, and the combinatory effect of HDVC with anti-PD-1 therapy was assessed. The results showed that HDVC significantly inhibited pancreatic tumor growth and prolonged survival in vivo. Mechanistically, HDVC enhanced LPS + IFN-γ-induced M1 macrophage polarization, at least in part through activation of the JAK2-STAT1 signaling pathway, without markedly increasing M2-associated features. The antitumor efficacy of HDVC was markedly attenuated upon macrophage depletion, supporting the involvement of macrophage-dependent immune modulation. Furthermore, HDVC enhanced the efficacy of anti-PD-1 therapy, accompanied by increased M1-like macrophages and CD8⁺ T-cell infiltration in the TME. These findings identify HDVC as a potential immunomodulator that remodels the immunosuppressive TME of pancreatic cancer through macrophage-centered immune remodeling, providing a rationale for further investigating HDVC-based combination strategies with ICIs in pancreatic cancer.